HDAC inhibitors and their potential applications to glioblastoma therapy

Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these lig...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamopoulou, Eleni, Naumann, Ulrike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805657/
https://www.ncbi.nlm.nih.gov/pubmed/24167760
http://dx.doi.org/10.4161/onci.25219
_version_ 1782477897120874496
author Adamopoulou, Eleni
Naumann, Ulrike
author_facet Adamopoulou, Eleni
Naumann, Ulrike
author_sort Adamopoulou, Eleni
collection PubMed
description Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these ligands, driving cytotoxic responses against glioblastoma cells that efficiently inhibit tumor growth.
format Online
Article
Text
id pubmed-3805657
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38056572013-10-28 HDAC inhibitors and their potential applications to glioblastoma therapy Adamopoulou, Eleni Naumann, Ulrike Oncoimmunology Author's View Natural killer (NK) cells are integral components of the antitumor immune response. The downregulation of ligands for NK-cell stimulatory receptors represents a strategy whereby glioblastoma cells can evade NK-cell attacks. Histone deacetylase inhibitors can stimulate the (re)expression of these ligands, driving cytotoxic responses against glioblastoma cells that efficiently inhibit tumor growth. Landes Bioscience 2013-08-01 2013-06-10 /pmc/articles/PMC3805657/ /pubmed/24167760 http://dx.doi.org/10.4161/onci.25219 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Adamopoulou, Eleni
Naumann, Ulrike
HDAC inhibitors and their potential applications to glioblastoma therapy
title HDAC inhibitors and their potential applications to glioblastoma therapy
title_full HDAC inhibitors and their potential applications to glioblastoma therapy
title_fullStr HDAC inhibitors and their potential applications to glioblastoma therapy
title_full_unstemmed HDAC inhibitors and their potential applications to glioblastoma therapy
title_short HDAC inhibitors and their potential applications to glioblastoma therapy
title_sort hdac inhibitors and their potential applications to glioblastoma therapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805657/
https://www.ncbi.nlm.nih.gov/pubmed/24167760
http://dx.doi.org/10.4161/onci.25219
work_keys_str_mv AT adamopouloueleni hdacinhibitorsandtheirpotentialapplicationstoglioblastomatherapy
AT naumannulrike hdacinhibitorsandtheirpotentialapplicationstoglioblastomatherapy

Ejemplares similares